Table 1.
Characteristics of participants
| Characteristic | Category | Number (%) |
|---|---|---|
| Gender | Male | 23 (54.8) |
| Female | 19 (45.2) | |
| Agea | Over 50 | 22 (52.4) |
| Under 50 | 20 (47.6) | |
| Employment status | Employed | 25 (59.5) |
| Unemployed | 1 (2.4) | |
| Housekeeper | 6 (14.3) | |
| Retired | 9 (21.4) | |
| Student | 1 (2.4) | |
| Marriage status | Single | 12 (28.6) |
| Married | 25 (59.5) | |
| Widowed | 3 (7.1) | |
| Divorce | 2 (4.8) | |
| Use of imatinib for more than 18 months | 36 (85.7) | |
| Imatinib utilisation | Prescription interruptionc | 12 (28.6) |
| PPR more than 90 %d | 38 (90.5) | |
| Disease phase at diagnosis | Chronic phase | 35 (83.3) |
| Accelerated or blast phase | 7 (16.7) | |
| Experience of progressionb | 13 (31.0) | |
| Treatment effect | CCyR at the 18th monthe | 36 (90.0) |
| MMR at the 18th monthf | 33 (84.6) |
aMean age and standard deviation: 50.0 ± 16.0 years
bProgression to accelerate or blast phase
cPrescription interruption: any gap of prescription covering days between two consecutive imatinib prescriptions for more than 30 days
d PPR prescription possession ratio, which refers to the proportion of medication covering days over the treatment period
e CCyR complete cytogenetic remissions
f MMR major molecular response